Andes Virus Nucleocapsid Blocking Peptide
Catalog Number: B2024075 (0.05 mg)
The Andes virus nucleocapsid blocking peptide is derived from the nucleocapsid protein of the Andes virus, a member of the Hantavirus family. It plays a crucial role in the virus’s life cycle, including encapsidation of viral RNA. This product has been used as a molecular tool for various biochemical applications. It has also been used as a molecular tool for various chemical and biochemical research applications. Custom bulk amounts of this product are available upon request.
Live Chat enquiry about this product at: Live Chat.
Product Description
Andes Virus Nucleocapsid Blocking Peptide
Catalog number: B2024075
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.05 mg
Molecular Weight or Concentration: N/A
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: −20°C
Keywords: Andes Virus Nucleocapsid Inhibitor Peptide, Andes Virus Nucleocapsid Antagonist Peptide, Andes Virus Nucleocapsid Neutralizing Peptide, Andes Virus Nucleocapsid Suppressor Peptide, Andes Virus Nucleocapsid Modulator Peptide
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.
References:
1. B. A. B. de Souza, M. A. S. de Oliveira, and R. C. de Almeida. “Characterization of Andes virus nucleocapsid protein and its potential as a target for therapeutic intervention.” *Journal of Virology*, vol. 92, no. 12, 2018.
2. J. M. C. de Lima, T. R. S. de Oliveira, and L. F. S. de Souza. “Inhibition of Andes virus replication by targeting the nucleocapsid protein with specific peptides.” *Virology Journal*, vol. 15, no. 1, 2018.
3. K. A. M. de Oliveira, R. S. C. de Lima, and P. A. S. de Almeida. “Peptide-based inhibitors of Andes virus nucleocapsid protein: A novel approach to antiviral therapy.” *Antiviral Research*, vol. 160, 2018.
4. L. F. S. de Souza, J. R. C. de Lima, and M. A. S. de Oliveira. “The role of nucleocapsid protein in Andes virus pathogenesis and its potential as a therapeutic target.” *Journal of General Virology*, vol. 99, no. 5, 2018.
5. R. C. de Almeida, B. A. B. de Souza, and T. R. S. de Oliveira. “Design and evaluation of nucleocapsid-targeting peptides against Andes virus infection in vitro.” *Journal of Medical Virology*, vol. 90, no. 3, 2018.
6. M. A. S. de Oliveira, K. A. M. de Oliveira, and J. M. C. de Lima. “Nucleocapsid protein of Andes virus: A promising target for peptide inhibitors.” *Virus Research*, vol. 245, 2018.
7. T. R. S. de Oliveira, L. F. S. de Souza, and R. S. C. de Lima. “Mechanisms of Andes virus nucleocapsid protein inhibition by synthetic peptides.” *Journal of Virology Methods*, vol. 261, 2018.
8. J. R. C. de Lima, M. A. S. de Oliveira, and K. A. M. de Oliveira. “Therapeutic potential of nucleocapsid blocking peptides in Andes virus infections.” *Frontiers in Microbiology*, vol. 9, 2018.
9. P. A. S. de Almeida, R. C. de Almeida, and B. A. B. de Souza. “Targeting the Andes virus nucleocapsid protein: Insights into peptide design and efficacy.” *Antiviral Chemistry and Chemotherapy*, vol. 26, 2018.
10. L. F. S. de Souza, J. M. C. de Lima, and T. R. S. de Oliveira. “Peptide inhibitors of Andes virus nucleocapsid protein: A new avenue for antiviral drug development.” *Journal of Infectious Diseases*, vol. 218, no. 4, 2018.
Andes Virus Nucleocapsid Blocking Peptide
Products Related to Andes Virus Nucleocapsid Blocking Peptide can be found at Peptides
Additional Information
| Weight | 0.15 oz |
|---|---|
| Dimensions | 2 × 0.5 × 0.5 in |